The Tides compound guide
BPC-157. TB-500. MOTS-c. Get to know the compounds people are talking about, the science behind them, and where access stands.
Explore care available todayAccess update · October 30, 2026
HHS has posted a draft conditional compounding policy naming BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV. It is not FDA approval. GetTides availability still depends on the exact product, pharmacy supply, clinical review and state requirements.
Read the HHS policy ↗ Read the draft-policy notice ↗Tissue & digestive research
Explore the compound at the center of the recovery conversation.
BPC-157 is included in the October HHS policy. That policy does not establish that it heals injuries or treats digestive disease.
Tides has not opened assessments or orders for this compound. Supply, formulation, clinical review and availability in your state must be confirmed before it can be offered. No launch date or price is confirmed.
Tissue research
Understand the name, the research and the new access policy.
The policy specifies TB-500 acetate. Evidence about the parent protein, thymosin beta-4, does not automatically establish the effects of this fragment.
Tides has not opened assessments or orders for this compound. Supply, formulation, clinical review and availability in your state must be confirmed before it can be offered. No launch date or price is confirmed.
Cellular & metabolic research
A closer look at a compound attracting interest in cellular biology.
MOTS-c is included in the October HHS policy. Inclusion is not proof of improved energy, weight loss or longevity.
Tides has not opened assessments or orders for this compound. Supply, formulation, clinical review and availability in your state must be confirmed before it can be offered. No launch date or price is confirmed.
Growth-hormone signaling
Sermorelin is back in the conversation. Check its status at Tides.
GetTides availability is not yet confirmed. Sermorelin is distinct from tesamorelin and is not one of the six compounds in the October HHS policy.
Tides has not opened assessments or orders for this compound. Supply, formulation, clinical review and availability in your state must be confirmed before it can be offered. No launch date or price is confirmed.
Aging research
Learn how research interest differs from established clinical benefit.
Epitalon is named in the October HHS policy. The policy does not establish an anti-aging or life-extension benefit.
Tides has not opened assessments or orders for this compound. Supply, formulation, clinical review and availability in your state must be confirmed before it can be offered. No launch date or price is confirmed.
Neurological research
Understand the policy update and the questions still to answer.
The policy specifies Semax free base for intranasal administration. This is not an approval for cognitive enhancement.
Tides has not opened assessments or orders for this compound. Supply, formulation, clinical review and availability in your state must be confirmed before it can be offered. No launch date or price is confirmed.
Inflammation research
Explore the compound and what the access policy actually covers.
KPV is named in the October HHS policy. Inclusion does not establish that a particular formulation treats inflammation or digestive symptoms.
Tides has not opened assessments or orders for this compound. Supply, formulation, clinical review and availability in your state must be confirmed before it can be offered. No launch date or price is confirmed.
No compounds match. Try another name.
The Compound Atlas
Explore 12 current Tides compounds through an interactive body map. Follow a pathway, inspect a structure and read the evidence.
Explore the bodyAnatomical highlights explain selected biology. They do not show drug distribution or promise a treatment benefit.